Cotización Bergenbio Asa - 0RU5

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Último Precio

4,600.00

Postura de Compra

0.00

Postura de Venta

0.00

Volume Operado de la Acción

1,716

0.00 Rango del Día 0.00

4,600.00 Rango de 52 semanas 4,600.00

Capitalización de Mercado [m]

12.368T

Precio Anterior

4,600.00

Precio de Apertura

Hora

1000

9.675

(O)

Última hora de negociación

03:36:36

Volumen financiero

Precio Promedio Ponderado

Volumen promedio (3 m)

722

Acciones en circulación

2,688,689,000

Rendimiento del Dividendo

Ratio Precio/Utilidad

-64,971.75

Beneficio por acción (BPA)

-0.07

turnover

354k

Beneficio neto

-190.4M

Sector

Meas & Controlling Dev, Nec

Industria

Meas & Controlling Dev, Nec

Sitio web

www.bergenbio.com

Sede

Bergen, Nor

Fundado

Bergenbio Asa is listed in the Meas & Controlling Dev sector of the London Stock Exchange with ticker 0RU5. The last closing price for Bergenbio Asa was kr4,600. Over the last year, Bergenbio Asa shares have traded in a share price range of kr 4,600.00 to kr 4,600.00.

Bergenbio Asa currently has 2,688,689,000 shares in issue. The market capitalisation of Bergenbio Asa is kr12.37 trillion. Bergenbio Asa has a price to earnings ratio (PE ratio) of -64971.75.

BerGenBio Appoints Olav Hellebø as CEO

BerGenBio Appoints Olav Hellebø as CEO PR Newswire BERGEN, Norway, Nov. 20, 2024 BERGEN, Norway, Nov. 20, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical...

BerGenBio Appoints Olav Hellebø as CEO

BerGenBio Appoints Olav Hellebø as CEO PR Newswire BERGEN, Norway, Nov. 20, 2024 BERGEN, Norway, Nov. 20, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical...

BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer

BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer PR Newswire BERGEN, Norway, Aug. 22, 2023...

BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer

BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer PR Newswire BERGEN, Norway, Aug. 22, 2023...

BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue

BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue PR Newswire BERGEN, Norway, May 26, 2023 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR...

BerGenBio ASA: Proposed partially underwritten rights issue

BerGenBio ASA: Proposed partially underwritten rights issue PR Newswire BERGEN, Norway, April 25, 2023 NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES...

BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR

BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR PR Newswire BERGEN, Norway, April 18, 2023 In addition to STK11 mutations, KEAP1m identified as being associated with...

BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR

BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR PR Newswire BERGEN, Norway, April 18, 2023 In addition to STK11 mutations, KEAP1m identified as being associated with...

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations PR Newswire BERGEN, Norway, March 9, 2023 - Global...

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations

BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations PR Newswire BERGEN, Norway, March 9, 2023 - Global...

Período †	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	4600	4600	4600	1788	4600	DE
4	4600	4600	4600	1277	4600	DE
12	4600	4600	4600	722	4600	DE
26	4600	4600	4600	2440	4600	DE
52	4600	4600	4600	90849	4600	DE
156	4600	4600	4600	77254	4600	DE
260	4600	4600	4600	48153	4600	DE

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
FARFerro-alloy Resources Limited	5.25p (123.40%)	27.99M
VELAVela Technologies Plc	0.0075p (36.36%)	205.95M
CASPCaspian Sunrise Plc	3.60p (28.57%)	9.37M
ROCRockpool Acquisitions Plc	2.25p (28.57%)	150k
RCGHRc365 Holding Plc	1.60p (28.00%)	2.96M
NTOGNostra Terra Oil And Gas Company Plc	0.0235p (-37.33%)	768.94M
SLFRSlf Realisation Fund Limited	1.02p (-27.66%)	293.37k
QUIZQuiz Plc	4.02p (-23.43%)	18.99k
PPSProton Motor Power Systems Plc	0.145p (-19.44%)	5.46M
KP2Kore Potash Plc	2.45p (-18.33%)	6.83M
NTOGNostra Terra Oil And Gas Company Plc	0.0235p (-37.33%)	768.94M
NTVONativo Resources Plc	0.0023p (0.00%)	517.61M
TRPTower Resources Plc	0.028p (1.82%)	449.24M
HAYDHaydale Graphene Industries Plc	0.115p (0.00%)	265.4M
UKOGUk Oil & Gas Plc	0.0245p (-1.01%)	220.73M